Analysts Set Enhabit, Inc. (NYSE:EHAB) Target Price at $12.08

Shares of Enhabit, Inc. (NYSE:EHABGet Free Report) have been given a consensus rating of “Reduce” by the seven brokerages that are covering the company, reports. Two analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $12.08.

EHAB has been the subject of a number of recent analyst reports. Oppenheimer reiterated a “market perform” rating on shares of Enhabit in a report on Thursday, March 7th. UBS Group upgraded Enhabit from a “sell” rating to a “neutral” rating and set a $9.50 target price on the stock in a research report on Thursday, March 7th. Finally, Jefferies Financial Group lowered their target price on Enhabit from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, March 6th.

Check Out Our Latest Report on EHAB

Enhabit Stock Performance

NYSE:EHAB opened at $10.25 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.53 and a current ratio of 1.53. Enhabit has a fifty-two week low of $7.12 and a fifty-two week high of $14.59. The company has a 50 day simple moving average of $10.20 and a two-hundred day simple moving average of $9.85. The company has a market capitalization of $514.14 million, a PE ratio of -6.33, a P/E/G ratio of 1.55 and a beta of 1.96.

Enhabit (NYSE:EHABGet Free Report) last posted its quarterly earnings data on Wednesday, March 6th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. Enhabit had a negative net margin of 7.69% and a positive return on equity of 1.55%. The company had revenue of $260.60 million for the quarter, compared to analyst estimates of $260.30 million. During the same period in the prior year, the firm posted $0.32 EPS. Research analysts anticipate that Enhabit will post 0.24 earnings per share for the current year.

Institutional Trading of Enhabit

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Enhabit during the third quarter worth $97,492,000. Vanguard Group Inc. acquired a new stake in shares of Enhabit in the 3rd quarter worth about $77,886,000. JANA Partners Management LP acquired a new stake in shares of Enhabit in the 3rd quarter worth about $20,532,000. State Street Corp bought a new position in Enhabit in the 3rd quarter valued at about $22,827,000. Finally, UBS Group AG boosted its stake in Enhabit by 7,973.5% during the 3rd quarter. UBS Group AG now owns 1,633,751 shares of the company’s stock valued at $18,380,000 after purchasing an additional 1,613,515 shares during the last quarter.

Enhabit Company Profile

(Get Free Report

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

Further Reading

Analyst Recommendations for Enhabit (NYSE:EHAB)

Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with's FREE daily email newsletter.